It was named after scientists from the Institute of Biochemical Physics. NM Emanuel (IBCP) RAS proposed using analysis of blood circulating tumor DNA (ctDNA) to predict the occurrence of breast cancer (BC) recurrence. The Ministry of Education and Science of the Russian Federation told socialbites.ca about this.
Circulating tumor DNA (ctDNA) are fragments of DNA from tumor cells that circulate freely in the bloodstream. Liquid biopsy is used to look for ctDNA; A blood sample is taken from a vein, then tumor DNA is isolated and tested.
The selection of samples for the determination of ctDNA is, as a rule, a simple procedure involving the collection of venous blood from the patient and its further processing. This makes it possible to obtain diagnostic material as often as desired. However, it is often difficult and often technically impossible to recover material using conventional tumor biopsy, including from the metastatic focus, in order to determine the biological characteristics of the tumor.
In the case of breast cancer, ctDNA analysis can be used both to detect relapses and for early diagnosis of this type of cancer, since the appearance of ctDNA together with changes in the blood flow characteristic of breast cancer occurs well ahead of the clinical manifestation of the disease. illness.
During breast cancer treatment, ctDNA analysis can be used to estimate the risk of cancer recurrence and to evaluate the effectiveness of various treatment regimens. Another important application of ctDNA research is its use to monitor the effectiveness of breast cancer treatment in real time.
“CtDNA can be detected in the blood plasma of breast cancer patients at early stages and appears to be a promising diagnostic marker. Many of the molecular abnormalities found in blood plasma ctDNA reflect genetic alterations present in the primary tumor.” Candidate of Biological Sciences, researcher at the Laboratory of Chemical Physics of Bioanalytical Processes at the Institute of Biochemical Physics ANM Emanuel RAS Zavarykina Tatyana.
former oncologist named Required examinations for all men over 40 years of age.